Fate Therapeutics Inc (NASDAQ:FATE) – Equities researchers at Leerink Swann issued their Q1 2018 EPS estimates for shares of Fate Therapeutics in a research report issued on Tuesday, Zacks Investment Research reports. Leerink Swann analyst M. Schmidt anticipates that the biopharmaceutical company will post earnings per share of ($0.22) for the quarter. Leerink Swann also issued estimates for Fate Therapeutics’ Q2 2018 earnings at ($0.22) EPS, Q3 2018 earnings at ($0.22) EPS and Q4 2018 earnings at ($0.23) EPS.
FATE has been the topic of a number of other reports. HC Wainwright lowered Fate Therapeutics from a “buy” rating to a “neutral” rating and set a $12.00 price target on the stock. in a report on Tuesday, March 6th. ValuEngine raised Fate Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, December 22nd. UBS Group lowered Fate Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, March 6th. Zacks Investment Research lowered Fate Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, January 22nd. Finally, Wedbush reaffirmed an “outperform” rating and set a $7.00 target price (down from $10.00) on shares of Fate Therapeutics in a report on Thursday, January 18th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. Fate Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $13.00.
Shares of Fate Therapeutics (FATE) traded down $0.34 on Wednesday, hitting $11.73. The stock had a trading volume of 765,927 shares, compared to its average volume of 788,455. The firm has a market capitalization of $689.16, a price-to-earnings ratio of -11.50 and a beta of 1.65. The company has a debt-to-equity ratio of 0.19, a current ratio of 9.29 and a quick ratio of 9.29. Fate Therapeutics has a 52 week low of $2.52 and a 52 week high of $14.45.
Fate Therapeutics (NASDAQ:FATE) last issued its quarterly earnings results on Monday, March 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05). The business had revenue of $1.03 million for the quarter, compared to analyst estimates of $1.02 million. Fate Therapeutics had a negative net margin of 1,046.08% and a negative return on equity of 71.00%. Fate Therapeutics’s revenue for the quarter was up .0% compared to the same quarter last year.
A number of large investors have recently added to or reduced their stakes in the stock. J. Goldman & Co LP acquired a new position in Fate Therapeutics during the fourth quarter worth about $1,277,000. 683 Capital Management LLC grew its holdings in Fate Therapeutics by 25.8% during the fourth quarter. 683 Capital Management LLC now owns 853,800 shares of the biopharmaceutical company’s stock worth $5,217,000 after acquiring an additional 175,000 shares during the period. Endurant Capital Management LP grew its holdings in Fate Therapeutics by 104.1% during the fourth quarter. Endurant Capital Management LP now owns 556,679 shares of the biopharmaceutical company’s stock worth $3,401,000 after acquiring an additional 283,979 shares during the period. Redmile Group LLC grew its holdings in Fate Therapeutics by 285.1% during the fourth quarter. Redmile Group LLC now owns 5,465,486 shares of the biopharmaceutical company’s stock worth $33,394,000 after acquiring an additional 4,046,428 shares during the period. Finally, Millennium Management LLC grew its holdings in Fate Therapeutics by 873.6% during the fourth quarter. Millennium Management LLC now owns 338,799 shares of the biopharmaceutical company’s stock worth $2,070,000 after acquiring an additional 303,999 shares during the period. 66.43% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.thelincolnianonline.com/2018/03/14/analysts-offer-predictions-for-fate-therapeutics-incs-q1-2018-earnings-fate.html.
About Fate Therapeutics
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.